ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2016
Evaluation of Castration-Resistant Prostate Cancer with Androgen Receptor-Axis Imaging.
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 20 citations in OpenAlex.
- Phase Ib study of enzalutamide with venetoclax in patients with metastatic castration-resistant prostate cancer.Cancer chemotherapy and pharmacology · 2025Article
- Designed ankyrin repeat proteins for detecting prostate-specific antigen expressionRSC chemical biology · 2023Article
- Understanding and targeting prostate cancer cell heterogeneity and plasticity.Seminars in cancer biology · 2022Review
- Prognostic and Theranostic Applications of Positron Emission Tomography for a Personalized Approach to Metastatic Castration-Resistant Prostate Cancer.International journal of molecular sciences · 2021Review
- Multimodality Imaging of Prostate Cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019Review
- Fluorine-18 Labeled Fluorofuranylnorprogesterone ([Molecules (Basel, Switzerland) · 2019Article
- Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses.Nature communications · 2018Article
- [The role of PSMA PET-CT in patients with metastatic prostate cancer].Der Radiologe · 2018Review
- Trends in oncologic hybrid imaging.European journal of hybrid imaging · 2018Review
- [The role of PSMA PET-CT in patients with metastatic prostate cancer].Der Urologe. Ausg. A · 2017Review
- Real-Time Transferrin-Based PET Detects MYC-Positive Prostate Cancer.Molecular cancer research : MCR · 2017Article
- Radiotheranostics in Prostate Cancer: Introduction and Overview.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Castration-resistant prostate cancer (CRPC) is the lethal form of prostate cancer, and more than 26,000 men will die from this disease in 2016. The pathophysiology of CRPC is clearly multifactorial, but most often, androgen receptor (AR) upregulation is associated with its earliest beginnings and the AR increase is part of the multimolecular complex including downstream effector proteins linked to AR (AR-axis) responsible for rapid proliferation and malignant features of the malignant cell. In both animal models and patients, glycolysis (Warburg effect) is also an early manifestation of CRPC transformation. At Memorial Sloan Kettering Cancer Center, we have focused our energies on imaging studies of the AR-axis in CRPC, using
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.